The advantages of using recombinant antibodies

Recombinant antibodies (rAbs) can be manufactured using synthetic genes expressed in an in vitro mammalian cell line. This is a biologically and chemically defined animal-free system unlike traditional hybridoma based technologies. Our approach to the manufacture of antibodies has a number of inherent advantages.

Reproducibility and control

Recombinant antibodies are biologically defined, with a known DNA and protein sequence, and as such it is ensured that the identical antibody is produced in each manufacturing batch. The possibility of genetic drift associated with hybridoma-based systems is removed completely and recombinant antibodies lack variability due to additional light chains that are often present in hybridomas. In addition, the manufacturing process is chemically defined, giving high purity and ultra-low batch-to-batch variability.


Unlike hybridoma-derived antibodies, recombinant antibodies can be reformatted to a different species, isotype or subtype. This opens up the possibility of switching antibodies into a more preferable format for in vitro or in vivo use. For more information please consult our antibody engineering page.

Antibody engineering

Recombinant antibodies can be engineered at the genetic level enabling production of recombinant antibody fragments, e.g. Fab and Fab2, bispecific antibodies, site-specific conjugation of antibodies and a myriad of other possibilities that are not available with conventional antibody technologies. For more information please consult our page on Antibody Engineering.


At Absolute Antibody our recombinant antibodies are expressed in a chemically defined serum-free mammalian expression system. This eliminates contamination from serum components, such as bovine albumin and IgG, leading to a product with very high purity (>98%).

Non-animal manufacturing

Although the antibody may originate from the immunisation of an animal , our manufacturing process  is entirely animal free. This alleviates animal welfare concerns associated with traditional monoclonal antibody manufacturing – specifically ascites production from hybridomas.